Clinical Trial Update: Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer [Phase 2]

View source ↗

Summary

This clinical trial update notes the completion of a phase 2 study evaluating nanoliposomal irinotecan (nal-IRI) with either 5-fluorouracil/leucovorin or gemcit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer
• Cholangiocarcinoma
• Extrahepatic Cholangiocarcinoma
• Intrahepatic Cholangiocarcinoma

Drugs mentioned

• 5-Fluorouracil (5-FU)
• CISPLATIN (cisplatin)
• Gemcitabine (Gemcitabine)
• Leucovorin (folinic acid)
• Onivyde (irinotecan hydrochloride liposome injection)

Snippet

Sponsor: AIO-Studien-gGmbH | Conditions: Adenocarcinoma Metastatic, Biliary Tract Cancer | Phase 2 | Status: COMPLETED